Literature DB >> 644545

Cyclophosphamide pneumonitis.

G J Mark, A Lehimgar-Zadeh, B D Ragsdale.   

Abstract

Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis. Although it has been reported previously in patients being treated for lymphoma, it occurred in this case in a man under treatment for glomerulonephritis. The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease. There may be an interval of one or more months after discontinuation of cyclophosphamide therapy before clinical or radiological improvement occurs.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 644545      PMCID: PMC470852          DOI: 10.1136/thx.33.1.89

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  11 in total

1.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-1972.

Authors: 
Journal:  N Engl J Med       Date:  1972-06-29       Impact factor: 91.245

2.  Letter: Reversible pulmonary edema following cyclophosphamide treatment.

Authors:  I Maxwell
Journal:  JAMA       Date:  1974-07-08       Impact factor: 56.272

Review 3.  The spectrum of drug-induced pulmonary disease.

Authors:  E C Rosenow
Journal:  Ann Intern Med       Date:  1972-12       Impact factor: 25.391

4.  Interstitial pneumonia after prolonged treatment with cyclophosphamide.

Authors:  A A Topilow; S P Rothenberg; T S Cottrell
Journal:  Am Rev Respir Dis       Date:  1973-07

5.  Alveolitis during procarbazine, vincristine and cyclophosphamide therapy.

Authors:  V A Dohner; H P Ward; R E Standord
Journal:  Chest       Date:  1972-11       Impact factor: 9.410

Review 6.  Symposium on immunosuppressive drugs. Late effects of immunosuppressive anticancer drugs.

Authors:  D A Karnofsky
Journal:  Fed Proc       Date:  1967 May-Jun

7.  Lung changes and chemotherapeutic agents in childhood. Report of a case associated with cyclophosphamide therapy.

Authors:  A E Rodin; M E Haggard; L B Travis
Journal:  Am J Dis Child       Date:  1970-10

8.  [Diffuse interstitial fibrosis of the lung in Hodgkin's disease treated by high doses of endoxan].

Authors:  R André; H Rochant; B Dreyfus; G Duhamel; J C Péchère
Journal:  Bull Mem Soc Med Hop Paris       Date:  1967 Nov 3-10

9.  Nonbacterial pneumonitis with multidrug antineoplastic therapy in breast carcinoma.

Authors:  F H Stutz; D C Tormey; J Blom
Journal:  Can Med Assoc J       Date:  1973-03-17       Impact factor: 8.262

10.  Cyclophosphamide therapy and interstitial pulmonary fibrosis.

Authors:  A R Patel; P C Shah; H L Rhee; H Sassoon; K P Rao
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

View more
  5 in total

Review 1.  Cyclophosphamide toxicity. Characterising and avoiding the problem.

Authors:  L H Fraiser; S Kanekal; J P Kehrer
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 2.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Hypersensitivity Pneumonitis Caused by Cephalosporins With Identical R1 Side Chains.

Authors:  Sang Hee Lee; Mi Hyun Kim; Kwangha Lee; Eun Jung Jo; Hye Kyung Park
Journal:  Allergy Asthma Immunol Res       Date:  2014-11-25       Impact factor: 5.764

Review 4.  Drug-induced pulmonary fibrosis.

Authors:  I Y Adamson
Journal:  Environ Health Perspect       Date:  1984-04       Impact factor: 9.031

5.  Cyclophosphamide-induced lung damage in mice: protection by a small preliminary dose.

Authors:  C H Collis; C M Wilson; J M Jones
Journal:  Br J Cancer       Date:  1980-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.